


Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2021
Document Type: USP Monographs
DocId: GUID-A82E46F3-242C-4E77-8871-910F5DAF2374_3_en-US
DOI: https://doi.org/10.31003/USPNF_M2123_03_01
DOI Ref: hr4ph

© 2025 USPC
Do not distribute

Omeprazole Magnesium



$C_{34}H_{36}MgN_6O_6S_2$ 713.12

(RS)-5-Methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt (2:1);
5-Methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinylbenzimidazole, (RS), magnesium salt (2:1) CAS RN®: 95382-33-5; UNII: 426QFE7XLK.

DEFINITION

Omeprazole Magnesium contains NLT 97.5% and NMT 102.0% of omeprazole magnesium ($C_{34}H_{36}MgN_6O_6S_2$), calculated on the anhydrous basis.

IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K
- B. The *Sample solution*, prepared and tested as directed in the test for *Content of Magnesium*, exhibits a significant absorption at the magnesium emission line at 285.2 nm.

Add the following:

▲ C. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.▲ (USP 1-May-2021)

ASSAY

Change to read:

• PROCEDURE

Solution A: 0.181 g/L of [sodium phosphate monobasic](#) and 1.118 g/L of [sodium phosphate dibasic anhydrous](#) in [water](#). If necessary, adjust with [phosphoric acid](#) to a pH of 7.6.

Solution B: Mix 11 mL of 0.25 M [sodium phosphate tribasic](#) with 22 mL of 0.5 M [sodium phosphate dibasic](#), and dilute with [water](#) to 100 mL.

Mobile phase: Acetonitrile and *Solution A* (35:65)

Standard solution: 0.05 mg/mL of [USP Omeprazole RS](#) prepared as follows. Transfer 10 mg of [USP Omeprazole RS](#) to a 200-mL volumetric flask, and dissolve in 10 mL of [methanol](#). Add 10 mL of *Solution B*, and dilute with [water](#) to volume.

Sample solution: 0.05 mg/mL of Omeprazole Magnesium prepared as follows. Transfer 10 mg of Omeprazole Magnesium to a 200-mL volumetric flask, and dissolve in 10 mL of [methanol](#). Add 10 mL of *Solution B*, and dilute with [water](#) to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 4.0-mm × 12.5-cm or 4.6-mm × 15-cm; 5-μm packing [L7](#). [NOTE—Alternatively, a 3.9-mm × 15-cm column; 4-μm packing [L1](#) may be used.]

Flow rate: 1.0 mL/min

Injection volume: 20 μL

System suitability

Sample: *Standard solution*

Suitability requirements

▲**Tailing factor:** NMT 1.5 ▲ (USP 1-May-2021)

Relative standard deviation: NMT ▲1.0% ▲ (USP 1-May-2021)

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of omeprazole magnesium ($C_{34}H_{36}MgN_6O_6S_2$) in the portion of Omeprazole Magnesium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times [M_{r_1}/(2 \times M_{r_2})] \times 100$$

r_U = peak response of omeprazole from the Sample solution

r_S = peak response of omeprazole from the Standard solution

C_S = concentration of [USP Omeprazole RS](#) in the Standard solution (mg/mL)

C_U = concentration of Omeprazole Magnesium in the Sample solution (mg/mL)

M_{r_1} = molecular weight of omeprazole magnesium, 713.12

M_{r_2} = molecular weight of omeprazole, 345.42

Acceptance criteria: 97.5%–102.0% on the anhydrous basis

OTHER COMPONENTS

• CONTENT OF MAGNESIUM

Lanthanum solution: Transfer 58.7 g of lanthanum oxide to a 1000-mL volumetric flask, wet the substance with some water, and dissolve by cautious addition of 250 mL of hydrochloric acid in 20- to 30-mL portions, cooling between the additions. Add water while stirring, cool to room temperature, and dilute with water to volume. [NOTE—Store the solution in a plastic bottle.]

Standard stock solution: 1000 µg/mL of magnesium in water, from a commercially prepared atomic absorption standard solution. [NOTE—Store the solution in a plastic bottle.]

Standard solution A: Transfer 10.0 mL of Standard stock solution to a 500-mL volumetric flask, add 50 mL of 1 N hydrochloric acid, and dilute with water to volume. Transfer 20.0 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. [NOTE—This solution contains 2 µg/mL of magnesium.]

Standard solution B: Combine 5.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.1 µg/mL).

Standard solution C: Combine 10.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.2 µg/mL).

Standard solution D: Combine 15.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.3 µg/mL).

Standard solution E: Combine 20.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.4 µg/mL).

Standard solution F: Combine 25.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.5 µg/mL). [NOTE—Concentrations of the Standard solutions and the Sample solution may be modified to fit the linear or working range of the instrument. When using instruments with a linear calibration graph, the number of Standard solutions can be reduced.]

Sample solution: Transfer 250 mg of Omeprazole Magnesium to a 100-mL volumetric flask, add 20 mL of 1 N hydrochloric acid, swirl until dissolved, and dilute with water to volume. Allow to stand for 30 min. Transfer 10.0 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. Transfer 10.0 mL of the solution to another 100-mL volumetric flask, add 4.0 mL of Lanthanum solution, and dilute with water to volume.

Blank: Transfer 4.0 mL of Lanthanum solution to a 100-mL volumetric flask, and dilute with water to volume.

Instrumental conditions

(See [Atomic Absorption Spectroscopy \(852\)](#).)

Mode: Atomic absorption spectrophotometry

Flame: Air–acetylene

Analytical wavelength: 285.2 nm

Analysis

Samples: Standard solution B, Standard solution C, Standard solution D, Standard solution E, Standard solution F, Sample solution, and Blank

Determine the concentration, C_S , in µg/mL, of magnesium in the Sample solution using the calibration graph.

Calculate the percentage of magnesium in the portion of Omeprazole Magnesium taken:

$$\text{Result} = (C_s/C_U) \times [100/(100 - F)] \times 100$$

C_s = concentration of magnesium in the *Sample solution* as calculated above (µg/mL)

C_U = concentration of Omeprazole Magnesium in the *Sample solution* (µg/mL)

F = content of water in Omeprazole Magnesium, as determined in *Specific Tests, Water Determination (%)*

Acceptance criteria: 3.30%–3.55% of magnesium content on the anhydrous basis

IMPURITIES

Change to read:

- **ORGANIC IMPURITIES**

Solution A: Prepare as directed in the Assay.

Mobile phase: Acetonitrile and *Solution A* (27.5: 72.5) ▲ (USP 1-May-2021) [Note—To improve the resolution, the composition may be changed to 1:3, if necessary.]

System suitability solution: 0.04 mg/mL each of [USP Omeprazole RS](#) and [USP Omeprazole Related Compound A RS](#) in *Mobile phase* ▲ (USP 1-May-2021)

Sample solution: 0.16 mg/mL of Omeprazole Magnesium in *Mobile phase*. [Note—Prepare this solution fresh.]

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 4.0-mm × 12.5-cm or 4.6-mm × 15-cm; 5-µm packing L7. [Note—Alternatively, a 3.9-mm × 15-cm column; 4-µm packing L1 may be used.]

Flow rate: 0.8–1.0 mL/min

Injection volume: 50 µL

Run time: NLT 4.5 times the retention time of omeprazole

System suitability

Sample: *System suitability solution*

Suitability requirements

Resolution: NLT 3 between omeprazole related compound A and omeprazole

Analysis

Sample: *Sample solution*

Calculate the percentage of any individual impurity in the portion of Omeprazole Magnesium taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response of any individual impurity from the *Sample solution*

r_T = sum of all the peak responses from the *Sample solution*

Acceptance criteria: See [Table 1](#).

Table 1

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|--|-------------------------|------------------------------|
| Omeprazole N-oxide ^a | 0.45 | 0.1 |
| ▲ (USP 1-May-2021) Omeprazole related compound A | 0.8 | 0.1 |
| Omeprazole | 1.0 | — |
| Any other individual impurity | — | 0.1 |

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|------------------|-------------------------|------------------------------|
| Total impurities | — | 0.5 |

^a 4-Methoxy-2-[(RS)-(5-methoxy-1*H*-benzimidazol-2-yl)sulfinyl]methyl]-3,5-dimethylpyridine 1-oxide.

SPECIFIC TESTS

- [WATER DETERMINATION \(921\), Method I](#): 7%–10%
- [OPTICAL ROTATION \(781S\), Procedures, Specific Rotation](#)

Sample solution: 10 mg/mL, in methanol

Acceptance criteria: +0.5° to –0.5°, measured at 20°

• COLOR OF SOLUTION

Analysis: Prepare a solution of Omeprazole Magnesium in methanol having a concentration of 20 mg/mL, and filter. Determine the absorbance of this solution at 440 nm, in 1-cm cells, using methanol as the blank.

Acceptance criteria: The absorbance is NMT 0.1.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, protected from light. Store at room temperature.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Omeprazole RS](#)

[USP Omeprazole Magnesium RS](#)

[USP Omeprazole Related Compound A RS](#)

Omeprazole sulfone;

5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1*H*-benzimidazole.

$C_{17}H_{19}N_3O_4S$ 361.42

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|----------------------------|---|---------------------------|
| OMEPRAZOLE MAGNESIUM | Documentary Standards Support | SM32020 Small Molecules 3 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM32020 Small Molecules 3 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 45(5)

Current DocID: GUID-A82E46F3-242C-4E77-8871-910F5DAF2374_3_en-US

DOI: https://doi.org/10.31003/USPNF_M2123_03_01

DOI ref: [hr4ph](#)